BioStock Investor Pitch: ExpreS2ion Biotechnologies

The biotechnology company ExpreS2ion Biotechnologies develops protein-based vaccines with its platform technology ExpreS2. The pipeline currently consists of projects in four indication areas: COVID-19, breast cancer, influenza and malaria. The company is now conducting a rights issue of SEK 73 million to finance the completion of preclinical studies in the breast cancer project ES2B-C001, as well as further develop the pipeline and strengthen the platform technology. CEO Bent U. Frandsen will talk more about ExpreS2ion's operations in today's BioStock Investor Pitch at 10:00.